脑转移瘤的肿瘤免疫微环境：愿景抗肿瘤免疫

作者：SCI全靠读

Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity

（IF: Cancer Discov., 39.397）

Brain metastasis (BrM) is a devastating complication of solid tumors associated with poor outcomes. Immune-checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, but determinants of response are incompletely understood. Given the rising incidence of BrM, improved understanding of immunobiologic principles unique to the central nervous system (CNS) and dissection of those that govern the activity of ICIs are paramount toward unlocking BrM-specific antitumor immunity. In this review, we seek to discuss the current clinical landscape of ICI activity in the CNS and CNS immunobiology, and we focus, in particular, on the role of glial cells in the CNS immune response to BrM.

人脑转移（BrM）是与生存率不良的本体瘤就其的严重并发症。免疫反应检查点抑制剂（ICI）已经彻底改变了乳癌的治疗，但对自由基的决定因素尚为不仅仅细致。鉴于BrM的肾癌不断上升，提高对大脑（CNS）特有的免疫反应生物学方法的了解，及对控制ICI社区活动方法的剖析，对于解锁BrM特异性有效成分免疫反应至关重要。在这篇综述之前，我们正试图讨论ICI社区活动在CNS和CNS免疫反应生物学之前的当前临床研究持续性，尤其是胶质细胞在CNS对BrM免疫反应自由基之前的起到。

Significance 意义

There is an urgent need to improve patient selection for and clinical activity of ICIs in patients with cancer with concomitant BrM. Increased understanding of the unique immunobiologic principles that govern response to ICIs in the CNS is critical toward identifying targets in the tumor microenvironment that may potentiate antitumor immunity.

对于原属BrM的乳癌患者，有鉴于改进ICIs的患者可选择和临床研究社区活动。提高对控制CNS之前对ICIs自由基的独特免疫反应生物学方法的了解，对于已确定肿瘤微环境之前可能加强有效成分免疫反应的靶点至关重要。

本文转载自其他com，不代表健康界观点和立场。如有内容和截图的权利人异议，叮嘱及时关联我们（邮箱：guikequan@hmkx.cn）